VHHs, the variable domains of camelid heavy chain-only antibodies, are gaining significant attention due to their unique advantages, including their ability to bind hidden epitopes and their adaptability for use in CAR-Ts and bi-/multi-specifics. ImmunoPrecise Antibodies (IPA) boasts over two decades of R&D experience with these potent antigen binding fragments. IPA leads in VHH discovery, utilizing phage libraries and rapid high-throughput single B cell technologies to produce diverse VHH panels against challenging targets. IPA’s comprehensive downstream characterization, data-driven down-selection, and engineering, including humanization, create a customizable and robust platform, accelerating therapeutic VHH development towards the clinic while minimizing risks.